Springworks Therapeutics Inc (SWTX)
$32.64
+0.81
(+2.54%)▲
Performance
- $32.06$33.07$32.64
1.78%
Downside
Day's Volatility :3.05%
Upside
1.3%
- $18.00$53.92$32.64
44.85%
Downside
52 Weeks Volatility :66.62%
Upside
39.47%
Returns
| Period | Springworks Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -13.43% | 5.7% | 0.0% |
6 Months | -28.5% | 6.7% | 0.0% |
1 Year | 37.67% | 18.4% | 0.0% |
3 Years | -45.98% | 20.8% | -20.2% |
Highlights
Market Capitalization | 2.4B |
Book Value | $7.5 |
Earnings Per Share (EPS) | -4.44 |
Wall Street Target Price | 67.53 |
Profit Margin | 0.0% |
Operating Margin TTM | -75.2% |
Return On Assets TTM | -35.4% |
Return On Equity TTM | -59.73% |
Revenue TTM | 86.2M |
Revenue Per Share TTM | 1.25 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 35.0M |
EBITDA | -318.7M |
Diluted Eps TTM | -4.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.32 |
EPS Estimate Next Year | -2.14 |
EPS Estimate Current Quarter | -1.11 |
EPS Estimate Next Quarter | -1.03 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 106.89%
Technicals Summary
Sell
Neutral
Buy
Springworks Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Springworks Therapeutics Inc | -22.33% | -28.5% | 37.67% | -45.98% | 75.37% |
 Regeneron Pharmaceuticals, Inc. | -13.97% | 8.28% | 24.49% | 82.67% | 258.6% |
 Novo Nordisk A/s | -14.46% | -7.16% | 29.25% | 137.43% | 348.48% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 77.93% | 59.32% | 38.21% | 249.95% |
 Vertex Pharmaceuticals Incorporated | -5.23% | 12.26% | 28.5% | 155.67% | 163.05% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Springworks Therapeutics Inc | NA | NA | NA | -3.32 | -0.6 | -0.35 | NA | 7.5 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Springworks Therapeutics Inc | Buy | $2.4B | 75.37% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 258.6% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 348.48% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 249.95% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.05% | 32.84 | -4.74% |
Insights on Springworks Therapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 5.44M → 59.73M (in $), with an average increase of 69.5% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -94.32M → -39.91M (in $), with an average increase of 63.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 21.6%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 84.2%
Institutional Holdings
FMR Inc
14.96%Vanguard Group Inc
8.81%BlackRock Inc
7.57%Deep Track Capital, LP
4.98%T. Rowe Price Associates, Inc.
4.85%Boxer Capital LLC
4.61%
Corporate Announcements
Springworks Therapeutics Inc Earnings
Springworks Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.
Organization | Springworks Therapeutics Inc |
Employees | 305 |
CEO | Mr. Saqib Islam J.D. |
Industry | Health Technology |
Discover More
Box, Inc.
$32.64
+2.54%
Ishares Core Aggressive Allocation Etf
$32.64
+2.54%
Goldman Sachs Activebeta Int
$32.64
+2.54%
John Wiley & Sons Inc
$32.64
+2.54%
Janux Therapeutics Inc
$32.64
+2.54%
Agree Realty Corp
$32.64
+2.54%
Triple Flag Precious Metals Corp
$32.64
+2.54%
Arcadium Lithium Plc
$32.64
+2.54%
Borgwarner Inc.
$32.64
+2.54%